Why Wegovy demand has outpaced supply — and what that means for you

You've searched for Wegovy and found a wall of 'out of stock' notices, here's the bigger picture

Imagine you've already spoken to a GP or a private prescriber, been told you're suitable for semaglutide, and then discovered the dose you need simply isn't available at your usual pharmacy this week. It's a genuinely common experience in the UK right now, and the frustration behind it is completely understandable.

The core problem is straightforward: clinical interest in Wegovy grew faster than Novo Nordisk's manufacturing capacity. When NICE published its recommendation for semaglutide under TA875 and NHS England began signalling a phased rollout through specialist weight management services, a large cohort of eligible patients wanted access at roughly the same time. Private prescribing volume rose alongside NHS commissioning discussions. The result was sustained, systemic demand that the supply chain was not scaled to meet.

Novo Nordisk responded by expanding production and, as the company has publicly confirmed, prioritising the UK among its markets. That has helped (shortages are less acute than they were in 2023 and early 2024) but stock gaps at individual pharmacies, particularly for mid-range maintenance doses, remain a reality. The MHRA has been clear throughout that this is a genuine supply issue, not a signal that the medicine is unsafe or that the market is unregulated. The relevant question for anyone in this position is not whether to panic, but how to navigate supply sensibly within a properly supervised clinical relationship.

What actually drives demand this high, and why the evidence matters

Wegovy's demand trajectory isn't primarily a social-media phenomenon, though coverage has certainly played a role. The more durable driver is the clinical data. The STEP 1 trial, published in the New England Journal of Medicine, reported an average weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose alongside lifestyle changes. For adults who have spent years with limited effective options, a figure like that (from a properly conducted randomised trial) is meaningful.

Add the MHRA's April 2026 approval of a dedicated single-dose 7.2mg pen, which trials associated with around 20.7% average weight loss at that higher dose, and the picture becomes one of a medicine that has continued to develop well beyond its launch formulation. People who started on semaglutide two years ago now have a higher-dose option to discuss with their prescriber, and those considering Wegovy de, the higher-strength formulation, can find full details on what that involves on our dedicated page. That keeps existing patients engaged with the treatment longer and brings new patients in who previously felt the evidence wasn't compelling enough.

Separately, conditions like lipedema and multiple sclerosis are being researched in relation to semaglutide, widening the population paying close attention to this medicine's development. Demand, in other words, is not a fad, it is the rational response of a large population to a genuinely effective licensed treatment becoming available after decades of limited options.

How shortage conditions create safety risks, and how to stay on the right side of them

When a medicine people need is hard to find through legitimate routes, the counterfeit market expands to fill the gap. The MHRA has warned publicly about fake weight-loss pens sold through social media and unverified online sellers, some seized pens contained insulin rather than semaglutide, which carries serious risk. Around 20 million doses of illegally traded weight-loss medicines (approximately £45 million street value) were seized in enforcement operations in 2025 alone. That's not a background statistical note; those are medicines that real people were close to injecting.

The safe-route markers are simple. A legitimate supply requires a prescription following a clinical assessment. Any route that bypasses that step is illegal and dangerous. You can verify any online pharmacy against the GPhC register at pharmacyregulation.org; if a seller cannot be found there, stop. Suspect sellers (including anyone offering these medicines without a clinical review) can be reported through the MHRA's Yellow Card scheme. The shortage is real, but it does not justify taking supply from an unverified source.

For those looking at their options in a shortage environment, it's also worth understanding that semaglutide is not the only licensed treatment in this space. Tirzepatide (Mounjaro) is a dual GIP and GLP-1 receptor agonist with a distinct mechanism; you can read a fuller comparison on our Wegovy overview page or explore what's currently available through our weight-loss treatments section. A prescriber can help you weigh which option makes clinical sense for you specifically, that conversation costs nothing to start at nume.

What a regulated UK pharmacy actually does when stock is tight

If you order through a GPhC-registered pharmacy and a particular strength is unavailable, the right response from that pharmacy is transparency: they tell you, they don't substitute without prescriber input, and they don't push you toward an unverified workaround. At nume, our clinical team reviews every order (not software) and a prescriber is across the detail before anything is dispensed.

When stock does arrive, the practical experience is fairly low-key: a DPD notification on your phone, a plain unbranded box, and the pen itself inside. It is a once-weekly injection, and if you'd like to see how the pen works before committing, our Wegovy demonstration video walks through the process clearly.

The pricing context is also worth stating plainly. Eli Lilly's September 2025 list price increase for tirzepatide pushed market prices higher across the board for GLP-1 medicines generally. On cost-related questions for semaglutide, our guide on where to buy Wegovy in the UK covers the landscape honestly, including what a legitimate private prescription typically costs. If you're ready to talk through your options with a prescriber, start your free consultation here, it's reviewed the same day by a real clinician.